Lozanski, Gerard

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 1,275

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood

Immune Cell Function and InteractionMultiple Myeloma Research and Treatments

Cited by 807

Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia

Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 584

BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 484

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Woyach, J. A., Smucker, K., Smith, L. L., Lozanski, A., Zhong, Y., Ruppert, A. S., Lucas, D., Williams, K., Zhao, W., Rassenti, L., et al. (2014) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 280

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Liu, T.-M., Woyach, J. A., Zhong, Y., Lozanski, A., Lozanski, G., Dong, S., Strattan, E., Lehman, A., Zhang, X., Jones, J. A., et al. (2015) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 178

Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity

Slominski, A. T., Janjetovic, Z., Fuller, B. E., Zmijewski, M. A., Tuckey, R. C., Nguyen, M. N., Sweatman, T., Li, W., Zjawiony, J., Miller, D., et al. (2010) · PLoS ONE

Vitamin D Research StudiesRetinoids in leukemia and cellular processes

Cited by 149

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood

Acute Myeloid Leukemia ResearchImmune Cell Function and Interaction

Cited by 93

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

Gupta, S. V., Sass, E. J., Davis, M. E., Edwards, R. B., Lozanski, G., Heerema, N. A., Lehman, A., Zhang, X., Jarjoura, D., Byrd, J. C., et al. (2011) · The AAPS Journal

Drug Transport and Resistance MechanismsAntibiotic Resistance in Bacteria

Cited by 81

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

Jones, D., Woyach, J. A., Zhao, W., Caruthers, S., Tu, H., Coleman, J., Byrd, J. C., Johnson, A. J., & Lozanski, G. (2017) · Leukemia

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 71

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

Sirenko, M., Lee, S., Sun, Z., Chaligne, R., Loghavi, S., Asimomitis, G., Brierley, C. K., Bernard, E., Cai, S. F., Myers, R. M., et al. (2025) · Cell Stem Cell

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 28